CO2022016662A2 - Derivados de triptamina deuterada y métodos de uso - Google Patents

Derivados de triptamina deuterada y métodos de uso

Info

Publication number
CO2022016662A2
CO2022016662A2 CONC2022/0016662A CO2022016662A CO2022016662A2 CO 2022016662 A2 CO2022016662 A2 CO 2022016662A2 CO 2022016662 A CO2022016662 A CO 2022016662A CO 2022016662 A2 CO2022016662 A2 CO 2022016662A2
Authority
CO
Colombia
Prior art keywords
deuterated
methods
tryptamine derivatives
tryptamine
derivatives
Prior art date
Application number
CONC2022/0016662A
Other languages
English (en)
Inventor
Alex Nivorozhkin
Michael Palfreyman
Original Assignee
Cybin Irl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/054340 external-priority patent/WO2021234608A1/en
Application filed by Cybin Irl Ltd filed Critical Cybin Irl Ltd
Publication of CO2022016662A2 publication Critical patent/CO2022016662A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se dirige a compuestos químicos y al uso de tales compuestos en el tratamiento de enfermedades asociadas con un receptor de serotonina 5-HT2.
CONC2022/0016662A 2020-05-19 2022-11-18 Derivados de triptamina deuterada y métodos de uso CO2022016662A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063026939P 2020-05-19 2020-05-19
US202063114738P 2020-11-17 2020-11-17
US202163157118P 2021-03-05 2021-03-05
PCT/IB2021/054340 WO2021234608A1 (en) 2020-05-19 2021-05-19 Deuterated tryptamine derivatives and methods of use

Publications (1)

Publication Number Publication Date
CO2022016662A2 true CO2022016662A2 (es) 2022-11-29

Family

ID=78608612

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0016662A CO2022016662A2 (es) 2020-05-19 2022-11-18 Derivados de triptamina deuterada y métodos de uso

Country Status (10)

Country Link
US (8) US20230219889A1 (es)
EP (1) EP4153564A4 (es)
JP (1) JP2023526856A (es)
KR (1) KR20230012501A (es)
CN (1) CN115667217A (es)
AU (1) AU2021276656A1 (es)
CA (1) CA3177454A1 (es)
CO (1) CO2022016662A2 (es)
IL (1) IL297492A (es)
MX (1) MX2022014605A (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP4038192A4 (en) 2019-10-01 2023-11-01 Empyrean Neuroscience, Inc. GENETIC MANIPULATION OF MUSHROOMS TO MODULATE TRYPTAMINE EXPRESSION
HUE059403T2 (hu) 2019-11-07 2022-11-28 Small Pharma Ltd Vegyületek
BR112022015377A2 (pt) 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de psilocina como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
WO2021155467A1 (en) 2020-02-04 2021-08-12 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders
CA3177454A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11773062B2 (en) * 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11324762B2 (en) 2020-10-08 2022-05-10 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US20220347195A1 (en) * 2021-05-03 2022-11-03 Mind Medicine, Inc. Psychedelics for treatment of pain
US11344564B1 (en) 2021-08-20 2022-05-31 Lennham Pharmaceuticals, Inc. Method of treatment based on reduced monoamine oxidase a activity
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
AU2022425541A1 (en) 2021-12-30 2024-06-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
AU2023207801A1 (en) * 2022-01-14 2024-06-27 Cybin Irl Limited Tryptamine compositions and methods
WO2024046837A1 (en) * 2022-08-31 2024-03-07 Cybin Irl Limited Tryptamine compounds, compositions, and methods of use
WO2024079314A1 (en) 2022-10-13 2024-04-18 Cybin Uk Ltd Method of administration of a parenteral formulation comprising a psychedelic agent

Family Cites Families (384)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA672478A (en) 1963-10-15 Heim Roger Psilocybin and psilocin
DE255749C (es)
DE265636C (es)
GB672478A (en) 1949-07-22 1952-05-21 Atlas Diesel Ab Method and means for connecting drill rods, drill steels or drill bits for rock drilling
GB912715A (en) 1958-02-21 1962-12-12 Sandoz Ltd 4-hydroxytryptamines
GB911946A (en) 1958-02-21 1962-12-05 Sandoz Ltd Psilocybin and psilocin and processes for their preparation
LU37646A1 (es) 1958-09-12
US3072530A (en) 1958-09-12 1963-01-08 Sandoz Ag Therapeutic indoles for psychic stimulation and relief of mental depression
US3078214A (en) 1958-09-12 1963-02-19 Sandoz Ag Treatment of mental disturbances with esters of indoles
FI34529A (fi) 1959-01-28 1964-10-10 Sandoz Ag Förfarande att i rent tillstånd tillvarataga de psykotropiskt verksamma föreningarna psilocybin och psilocin ur svamparter
US3192111A (en) 1959-02-16 1965-06-29 Sandoz Ltd Method of inducing therapeutic tranquilization with psilocybin and psilocin
GB981192A (en) 1960-03-30 1965-01-20 Westminster Bank Ltd Improvements in or relating to 4 hydroxytryptamine esters
GB982738A (en) 1961-06-05 1965-02-10 Ici Ltd 3-aminoalkylindoles
US3444174A (en) 1966-10-05 1969-05-13 American Cyanamid Co Substituted 4,7-dihydroindoles
US3583972A (en) 1969-06-11 1971-06-08 Upjohn Co N-dealkylation of cyclic tertiary amines
US3686213A (en) 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
JPS55105664A (en) 1979-02-08 1980-08-13 Kawaken Fine Chem Co Ltd Preparation of tryptamine
US4855325A (en) 1985-01-16 1989-08-08 Naftchi Nosrat E Treatment of mammals suffering from damage to the central nervous system
EP0152379A3 (de) 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US6107499A (en) 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
WO1991001756A1 (en) 1989-08-11 1991-02-21 Skolnick Malcolm H Method for chemical promotion of the effects of low current transcranial electrostimulation
US5258379A (en) 1990-05-04 1993-11-02 Eli Lilly And Company Method of inhibiting gastric acid secretion with n-arylpiperazines
US5158956A (en) 1990-05-04 1992-10-27 Eli Lilly And Company Method of inhibiting gastric acid secretion with benzodioxanes
US5340838A (en) 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CS276073B6 (cs) 1990-08-14 1992-03-18 Mikrobiologicky Ustav Csav Způsob přípravy biomasy s obsahem psilocybinu a peilociau ze etopkovýtrusá houby
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
FR2707639B1 (fr) 1993-06-30 1995-10-13 Pf Medicament Nouveaux composés indoliques dérivés d'arylamines comme ligands sélectifs des récepteurs 5HT1D et 5HT1B.
US5417987A (en) 1993-09-16 1995-05-23 Board Of Supervisors Of Louisiana State University Method for controlling bivalves such as zebra mussels
JPH0827020A (ja) 1994-07-19 1996-01-30 Mitsubishi Chem Corp 破骨細胞形成促進及び骨吸収剤
JPH0827029A (ja) 1994-07-19 1996-01-30 Fujisawa Pharmaceut Co Ltd ５ｈｔ１ 作動薬の新規医薬用途
US6207396B1 (en) 1995-11-20 2001-03-27 Microgenics Corporation Immunoassay reagents and methods for determination of LSD and LSD metabolites
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
EP0962464A3 (en) 1996-01-23 2004-02-11 Qiagen Genomics, Inc. Methods and compositions for detecting binding of ligand pair using non-fluorescent label
US6027890A (en) 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
EP0992511B1 (en) 1996-01-23 2009-03-11 Operon Biotechnologies, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
KR100482917B1 (ko) 1996-01-23 2005-11-11 퀴아진 지노믹스, 인코포레이티드 핵산분자의서열을결정하는방법및이를위한조성물
CN1515541A (zh) 1996-01-23 2004-07-28 ռ�˹ 利用非荧光标记检测配体对结合的方法和组合物
FR2744361B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
ES2200355T3 (es) 1997-07-22 2004-03-01 Qiagen Genomics Inc Metodos y composiciones para analizar acidos nucleicos por espectrometria de masas.
AU2775299A (en) 1998-02-20 1999-09-06 Microgenics Corporation Immunoassays for determination of lsd and lsd metabolites
EP1066523A2 (en) 1998-03-27 2001-01-10 Microgenics Corporation Confirmatory assays for small molecule drugs
US6306616B1 (en) 1998-03-27 2001-10-23 Microgenics Corporation Adsorption type confirmatory assays
AU3230299A (en) 1998-05-29 1999-12-09 Armacel Pty Limited An anchor mounting and installation method
AU4984899A (en) 1998-07-14 2000-02-07 Adams Food Ltd. Nutritionally active composition for hardening fingernails
MXPA01001180A (es) 1998-07-31 2002-04-24 Vela Pharmaceuticals Inc Metodos y composiciones para el tratamiento y la prevencion de abuso de sustancias empleando moclobemida.
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US20010008641A1 (en) 1998-11-25 2001-07-19 R. Douglas Krotzer Nutritionally active composition for bodybuilding
PT1149078E (pt) 1998-12-11 2006-07-31 Univ Virginia Commonwealth Ligandos receptores de 5-ht6 selectivos
EP1693366A1 (en) 1998-12-11 2006-08-23 Virginia Commonwealth University Selective 5-HT 6 receptor ligands
US6403808B1 (en) 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
WO2001095903A1 (en) 2000-06-15 2001-12-20 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
WO2002005851A2 (en) 2000-07-19 2002-01-24 Pitmy International N.V. Enhancement of the action of central and peripheral nervous system agents
WO2002024865A2 (en) 2000-09-19 2002-03-28 Microbia, Inc. Modulation of secondary metabolite production by zinc binuclear cluster proteins
AU2002211176A1 (en) 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3
WO2002036113A1 (en) 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US20030096013A1 (en) 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
EP1379239B1 (en) 2001-03-29 2007-09-12 Eli Lilly And Company N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US7132287B2 (en) 2001-06-18 2006-11-07 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5HT-1A agonists
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
US20030078231A1 (en) 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
US20030007961A1 (en) 2001-06-22 2003-01-09 Wilburn Michael D. Orthomolecular vitamin E derivatives
WO2003016903A2 (de) 2001-08-20 2003-02-27 Walter Pils Vorrichtung und verfahren zum nachweis eines analyten
AT501069A1 (de) 2001-08-20 2006-06-15 Walter Ing Pils Vorrichtung und verfahren zum nachweis eines analyten
ATE496917T1 (de) 2001-12-20 2011-02-15 Randox Lab Ltd Haptene, immunogene, antikörper und konjugate für 2-oxo-3-hydroxy lsd
US20040258617A1 (en) 2002-06-17 2004-12-23 Pearl Technology Holdings, Llc. Physical, chemical, and isotopic (atomic) labels
DK1537113T5 (da) 2002-06-21 2011-01-10 Suven Life Sciences Ltd Arylalkylindoler med serotoninreceptoraffinitet anvendelige som terapeutiske midler, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NZ537770A (en) 2002-06-21 2007-03-30 Suven Life Sciences Ltd Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
US11180781B2 (en) 2016-08-21 2021-11-23 Insectergy, Llc Biosynthetic cannabinoid production methods
US10738268B2 (en) 2016-08-21 2020-08-11 Insectergy, Llc Cannabis nanoemulsion methods
JP4726483B2 (ja) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
AU2003250106B2 (en) 2002-07-18 2009-11-26 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
EP1534239A2 (en) 2002-08-05 2005-06-01 Baxter International Inc. Preparation of submicron sized particles with polymorph control and new polymorph of itraconazole
CN1688288A (zh) 2002-08-05 2005-10-26 巴克斯特国际公司 具有多晶型控制的亚微米粒度颗粒的制备和新多晶型伊曲康唑
WO2004025268A2 (en) 2002-09-13 2004-03-25 Carnegie Mellon University Optical biosensors and methods of use thereof
AU2003273977B2 (en) 2002-10-11 2007-07-12 Idea Ag Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
AU2003304211A1 (en) 2002-10-30 2005-01-04 The Regents Of The University Of California Direct micro-patterning of lipid bilayers using uv light and selected uses thereof
JP4174016B2 (ja) 2003-07-11 2008-10-29 株式会社ビーエル 競合法によるサイロシン類のイムノクロマトグラフィー検出法及びテストキット
EP1670444B1 (en) 2003-10-03 2011-04-27 Veijlen N.V. Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases
US20050288616A1 (en) 2004-06-28 2005-12-29 Smiths Detection, Inc. Sampling swab
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
EP1799640A4 (en) 2004-09-27 2009-09-02 Organix Inc AS SEROTONINSELECTIVE ACTIVE SUBSTANCES SUITABLE INDOL COMPOUNDS
WO2007066240A2 (en) 2005-01-10 2007-06-14 Smiths Detection Inc. Sampling swab
DE102005008312A1 (de) 2005-02-17 2006-08-24 Birds Pharma Gmbh Berolina Innovative Research & Development Services Verwendung deuterierter N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]acatamide und deren pharmazeutisch verträglicher Salze sowie diese Verbindungen enthaltende Arzneimittel
WO2007024741A2 (en) 2005-08-24 2007-03-01 National Jewish Medical And Research Center Methods for treatment of thiol-containing compound deficient conditions
EP2998288B1 (en) 2005-12-01 2022-08-24 ACADIA Pharmaceuticals Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
US20080101995A1 (en) 2005-12-16 2008-05-01 Smiths Detection Inc. Ion mobility spectrometer having improved sample receiving device
CA2640502A1 (en) 2006-01-30 2007-08-02 Max-Planck Gesellschaft Zur Foerderung Der Wissenschaften E.V. Pesticidal composition comprising indole derivates
US20090028796A1 (en) 2006-01-30 2009-01-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Pesticidal composition comprising indole derivates
DK4282332T3 (da) 2006-02-22 2024-06-24 Dexcom Inc Analytsensor
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
GB0606147D0 (en) 2006-03-28 2006-05-10 Bioniqs Ltd Method
WO2008003028A2 (en) 2006-06-28 2008-01-03 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
US20080010318A1 (en) 2006-07-05 2008-01-10 Samsung Electronics Co., Ltd. Apparatus and method for managing content stored in portable digital device
WO2008016677A2 (en) 2006-08-02 2008-02-07 Auspex Pharmaceuticals, Inc. Preparation and utility of deuterated amphetamines
DE102006040027B3 (de) 2006-08-25 2008-06-26 Christian Beer Vakuumförderer zum Transport, Ablegen und Stapeln von flächenförmigen Gegenständen
CN101687788A (zh) 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 取代的吲哚
US8653106B2 (en) 2010-07-30 2014-02-18 Pisgah Laboratories, Inc. Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder
US20120183600A1 (en) 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
KR20100014392A (ko) 2007-03-09 2010-02-10 첼시 쎄라퓨틱스, 인코포레이티드 섬유근통 치료용 드록시도파 및 약학 조성물
WO2008112773A2 (en) 2007-03-12 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
AR065728A1 (es) 2007-03-15 2009-06-24 Auspex Pharmaceuticals Inc Fenetilaminas sustituidas con actividad de serotoninergico y/o norepinefrinergico
JP2010532672A (ja) 2007-03-30 2010-10-14 デューク ユニバーシティ 薬剤を送給するための装置および方法
WO2008122990A1 (en) 2007-04-04 2008-10-16 Almet Corporation Limited Compacting upflow extractor and method of using it
EP2032587A2 (en) 2007-04-18 2009-03-11 Teva Pharmaceutical Industries Ltd. Rosuvastatin intermediates and process for the preparation of rosuvastatin
JP2010526820A (ja) 2007-05-07 2010-08-05 チェルシー・セラピューティクス，インコーポレイテッド 気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
NO20073112A (no) 2007-06-18 2008-09-15 Ziebel As Hylseventil
DE602007012080D1 (de) 2007-08-01 2011-03-03 Esteve Labor Dr Kombination von mindestens zwei 5-HT6-Liganden
BRPI0815089A2 (pt) 2007-08-06 2014-09-30 Synosia Therapeutics Inc Métodos para tratar um paciente que sofre de ou suscetível a pelo menos um sintoma de abuso de, dependência sobre, ou retirada de pelo menos uma substância, para tratar pelo menos uma fase de dependência de substância sobre pelo menos uma substância em um paciente, e para tratar pelo menos uma fase de dependência à cocaína em um paciente.
AU2014202047A1 (en) 2007-08-06 2014-05-01 Biotie Therapies, Inc. Methods for treating dependence
AU2016208412A1 (en) 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
US20090043184A1 (en) 2007-08-08 2009-02-12 Edwards Lifesciences Corporation Catheter and probe for measuring analytes or other parameters
EP2200610B1 (en) 2007-09-21 2018-01-10 Acadia Pharmaceuticals Inc. Co-administration of pimavanserin with other agents
AU2008310883A1 (en) 2007-10-09 2009-04-16 Hamann, Mark T Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
WO2009097596A1 (en) 2008-01-31 2009-08-06 Paul Griffin Compositions and methods for the treatment of chronic infections
US8329663B2 (en) 2008-01-31 2012-12-11 Paul Griffin Compositions and methods for the treatment of chronic infections
US20090318527A1 (en) 2008-02-11 2009-12-24 Howard Sard Indole compounds and methods of use thereof
EP2280703A1 (en) 2008-03-12 2011-02-09 Københavns Universitet (University Of Copenhagen) Use of npy y5 receptor antagonists for the prevention of psychostimulant and opioid abuse
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
EP3308777A1 (en) 2008-06-19 2018-04-18 LTS Lohmann Therapie-Systeme AG Composition for transdermal delivery of cationic active agents
CA2732823A1 (en) 2008-08-13 2010-02-18 George Mason Intellectual Properties, Inc. Ex vivo therapeutic screening of living bone marrow cells for multiple myeloma
US8560039B2 (en) 2008-09-19 2013-10-15 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
WO2010088911A1 (en) 2009-02-06 2010-08-12 Egalet A/S Pharmaceutical compositions resistant to abuse
JP5550839B2 (ja) 2009-02-09 2014-07-16 株式会社 資生堂 美白剤
KR101767273B1 (ko) 2009-03-11 2017-08-10 오메로스 코포레이션 중독의 예방 및 치료용 조성물 및 방법
WO2010121022A1 (en) 2009-04-15 2010-10-21 Research Triangle Institute Monoamine reuptake inhibitors
WO2010124089A2 (en) 2009-04-22 2010-10-28 Synosia Therapeutics, Inc. Methods for treating dependence
WO2010151258A1 (en) 2009-06-24 2010-12-29 The Board Of Regents Of The University Of Oklahoma Methods of treating psychological conditions
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2473199A1 (en) 2009-08-31 2012-07-11 Brain Watch Ltd. Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders
WO2011028875A1 (en) 2009-09-03 2011-03-10 Wake Forest University Health Sciences Immunogenic conjugates for producing immune responses to drugs of abuse and methods of use
MY163517A (en) 2009-09-16 2017-09-15 Philip Morris Products Sa Improved device and method for delivery of a medicament
EP2482724A2 (en) 2009-09-30 2012-08-08 Dexcom, Inc. Transcutaneous analyte sensor
CN102115455A (zh) 2009-12-30 2011-07-06 北京德众万全药物技术开发有限公司 一种赛洛多辛关键中间体的制备方法
JP5846696B2 (ja) 2010-05-10 2016-01-20 サジティス・インコーポレイテッド アルキルケタールエステルを含有する個別健康管理用処方物および製造方法
WO2011140607A1 (en) 2010-05-14 2011-11-17 Keating Charlotte L A method of treatment and diagnosis
WO2011140608A1 (en) 2010-05-14 2011-11-17 Keating Charlotte L Neuropsychopharmacological treatment regimes for treating psychological disorders
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
US20110319728A1 (en) 2010-06-29 2011-12-29 Edwards Lifesciences Corporation Blood parameter sensor and flow control system, method and computer program product
CN103221070B (zh) 2010-08-30 2019-07-12 哈佛大学校长及研究员协会 用于狭窄病变和溶解血栓疗法的切变控制释放
AU2011313814B2 (en) 2010-10-07 2015-12-24 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases
WO2012058337A2 (en) 2010-10-27 2012-05-03 Dexcom, Inc. Continuous analyte monitor data recording device operable in a blinded mode
WO2012058769A1 (en) 2010-11-03 2012-05-10 Mcmaster University Method of treating mucosal inflammation
WO2012085919A2 (en) 2010-12-22 2012-06-28 Exonoid Medical Devices Ltd. Method and system for drug delivery
TW201242600A (en) 2011-01-18 2012-11-01 Targacept Inc Treatment of cognitive dysfunction in schizophrenia
WO2012134436A1 (en) 2011-03-28 2012-10-04 Flir Systems, Inc. Detection of analytes including drugs
US8844007B2 (en) 2011-04-08 2014-09-23 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
WO2012173701A1 (en) 2011-06-16 2012-12-20 President And Fellows Of Harvard College Novel rodent control agents and uses thereof
EP2551675A1 (en) 2011-07-28 2013-01-30 Chiron AS Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use
US10575762B2 (en) 2011-08-05 2020-03-03 Dexcom, Inc. Systems and methods for detecting glucose level data patterns
US20130053666A1 (en) 2011-08-26 2013-02-28 Dexcom, Inc. Polymer membranes for continuous analyte sensors
CN107095680B (zh) 2011-09-23 2020-09-08 德克斯康公司 用于处理和传输传感器数据的系统和方法
WO2013064690A1 (de) 2011-11-04 2013-05-10 Chv Pharma Gmbh & Co. Kg Inhalator sowie verfahren zum erzeugen eines aerosols
CA2861975C (en) 2011-12-15 2022-05-31 Becton, Dickinson And Company System for improved interpretation of physiological data and presentation of physiological condition management information
GB201202223D0 (en) 2012-02-09 2012-03-28 Randox Lab Ltd Immunoassay for pyrrolidinophenones
EP2828385B1 (en) 2012-03-23 2018-02-07 Codexis, Inc. Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
US10881339B2 (en) 2012-06-29 2021-01-05 Dexcom, Inc. Use of sensor redundancy to detect sensor failures
US8986677B2 (en) 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
WO2014026044A2 (en) 2012-08-08 2014-02-13 Presage Biosciences, Inc. Extrusion methods and devices for drug delivery
WO2014035473A1 (en) 2012-08-31 2014-03-06 Zoll Medical Corporation Cardiac resuscitation methods and kits
US20150231300A1 (en) 2012-10-28 2015-08-20 Peritech Pharma Ltd. Pharmaceutical liquid adhesive compositions for treatment of anorectal disorders
EP2914174A4 (en) 2012-10-31 2016-07-06 Edwards Lifesciences Corp SENSOR SYSTEMS AND METHOD FOR USE THEREOF
WO2014078374A2 (en) 2012-11-13 2014-05-22 Presage Biosciences, Inc. Methods for multiplexed drug evaluation
US20140242722A1 (en) 2013-02-27 2014-08-28 Medtech Detect, Llc Article and method for detection of a drug in a liquid medium
US10085994B2 (en) 2013-03-10 2018-10-02 Peritech Pharma Ltd. Topical compositions and methods of treatment of topical disorders
WO2014152182A1 (en) 2013-03-15 2014-09-25 President And Fellows Of Harvard College Deuterated heterocyclic inhibitors of necroptosis
EP2983473A4 (en) 2013-03-15 2016-11-23 Als Mountain Llc PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONINERGIC AGENT AND METHODS OF USING SAME
US9561183B2 (en) 2013-03-15 2017-02-07 Children's National Medical Center Prussian blue-inspired constructs for multimodal imaging and therapy
EP2968125A1 (en) 2013-03-15 2016-01-20 BioChemics, Inc. Topical formulations and methods for drug delivery
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
MY170380A (en) 2013-03-15 2019-07-26 Philip Morris Products Sa Aerosol-generating system with differential heating
KR102278193B1 (ko) 2013-05-21 2021-07-19 필립모리스 프로덕츠 에스.에이. 전기 가열식 에어로졸 전달 시스템
CA2910548C (en) 2013-05-21 2021-06-22 Philip Morris Products S.A. Aerosol-generating system comprising a delivery enhancing compound source and a medicament source
CN105792942B (zh) 2013-10-09 2019-04-16 佐治亚-太平洋化工品有限公司 捕收剂组合物及其制备和应用方法
KR101629502B1 (ko) 2013-10-23 2016-06-10 주식회사 엘지생활건강 세정효과가 우수한 저자극 클렌징 워터 화장료 조성물
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
TW201605856A (zh) 2013-11-01 2016-02-16 艾尼納製藥公司 ５－ＨＴｃ受體促效劑
US9974470B2 (en) 2013-11-07 2018-05-22 Dexcom, Inc. Systems and methods for a continuous monitoring of analyte values
EP4307316A3 (en) 2013-11-14 2024-04-10 DexCom, Inc. Indicator and analytics for sensor insertion in a continuous analyte monitoring system and related methods
US10004435B2 (en) 2013-11-14 2018-06-26 Dexcom, Inc. Devices and methods for continuous analyte monitoring
EP4309570A1 (en) 2013-12-16 2024-01-24 DexCom, Inc. Systems and methods for monitoring and managing life of a battery in an analyte sensor system worn by a user
SG11201605012UA (en) 2013-12-19 2016-07-28 Philip Morris Products Sa Aerosol-generating system for generating and controlling the quantity of nicotine salt particles
EP2886153A1 (de) 2013-12-20 2015-06-24 LTS LOHMANN Therapie-Systeme AG System für die transdermale Abgabe von Wirkstoff
WO2015122964A1 (en) 2014-02-11 2015-08-20 Dexcom, Inc. Packaging system for analyte sensors
WO2015127556A1 (en) 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating defecation in a patient in need thereof
WO2015127558A1 (en) 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
CN103816150A (zh) 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
WO2015164541A1 (en) 2014-04-22 2015-10-29 Presage Biosciences, Inc. Methods and devices for evaluating drug candidates
WO2015187289A1 (en) 2014-06-03 2015-12-10 Pop Test Abuse Deterrent Technology Llc Drug device configured for wireless communication
IL273507B2 (en) 2014-06-30 2024-06-01 Syqe Medical Ltd Methods, devices and systems for administering active substances through the lungs
CA2994218A1 (en) 2014-07-30 2016-02-04 Cleveland Biolabs, Inc. Flagellin compositons and uses
WO2016033204A2 (en) 2014-08-26 2016-03-03 Echo Therapeutics, Inc. Differential biosensor system
US20160067711A1 (en) 2014-09-09 2016-03-10 The Regents Of The University Of Michigan Systems and methods for single cell isolation and analysis
MX2017003439A (es) 2014-09-17 2017-12-04 Mundipharma International Corporation Ltd Formas cristalinas de inhibidores de tirosina cinasa y sus sales.
US10332286B2 (en) 2014-10-06 2019-06-25 Dexcom, Inc. System and method for data analytics and visualization
MA41557A (fr) 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
CN112716051B (zh) 2015-03-27 2024-04-19 菲利普莫里斯生产公司 包括破裂部分的气溶胶生成系统
WO2016156212A1 (en) 2015-03-27 2016-10-06 Philip Morris Products S.A. Aerosol-generating system comprising integrated piercing element
WO2016161138A1 (en) 2015-03-31 2016-10-06 Stamets Paul Edward Antiviral activity from medicinal mushrooms and their active constituents
CA2952818A1 (en) 2015-05-01 2016-11-10 Eran Eilat Compositions for the treatment of epistaxis
CA2968703A1 (en) 2015-05-19 2016-11-24 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
US20180147142A1 (en) 2015-05-19 2018-05-31 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
CA2990843A1 (en) 2015-09-10 2017-03-16 Dexcom, Inc. Transcutaneous analyte sensors and monitors, calibration thereof, and associated methods
US10441316B2 (en) 2015-09-11 2019-10-15 Pop Test LLC Intradermal applicator/analyte sensor placement using fluorescence
WO2017112398A1 (en) 2015-12-21 2017-06-29 Dexcom, Inc. Continuous analyte monitoring system power conservation
DE202016009211U1 (de) 2015-12-30 2024-04-08 Dexcom, Inc. Systeme für transkutane Analytsensoren
CZ307719B6 (cs) 2015-12-31 2019-03-20 Vysoká škola chemicko-technologická v Praze Použití derivátu tryptaminu
US20170210704A1 (en) 2016-01-21 2017-07-27 Enlibrium Inc Deutero-phenformin derivatives
US10668030B2 (en) 2016-04-21 2020-06-02 University Of Kentucky Research Foundation Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
WO2017189528A1 (en) 2016-04-26 2017-11-02 Ecolab USA, Inc. Corrosion inhibitor compositions and methods of using same
CA3211813A1 (en) 2016-05-02 2017-11-09 Dexcom, Inc. System and method for providing alerts optimized for a user
DE102016014603A1 (de) 2016-06-30 2018-01-04 Thomas Herkenroth Synthetisches Ayahuasca
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
CA3029252A1 (en) 2016-08-12 2018-02-15 Dexcom, Inc. Systems and methods for health data visualization and user support tools for continuous glucose monitoring
US20210137137A1 (en) 2016-08-21 2021-05-13 Insectergy, Llc Insect production systems and methods
US20200229411A1 (en) 2016-08-21 2020-07-23 Insectergy, Llc Insect production systems and methods
WO2018039642A1 (en) 2016-08-26 2018-03-01 Exciva Ug (Haftungsbeschränkt) Compositions and methods thereof
CA3075124C (en) 2016-09-09 2023-05-02 Dexcom, Inc. Systems and methods for cgm-based bolus calculator for display and for provision to medicament delivery devices
WO2018057576A1 (en) 2016-09-22 2018-03-29 Auspex Pharmaceuticals, Inc. Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
AU2017345135B9 (en) 2016-10-18 2020-02-13 Dexcom. Inc. System and method for communication of analyte data
WO2018089375A1 (en) 2016-11-09 2018-05-17 Dexcom, Inc. Systems and methods for technical support of continuous analyte monitoring and sensor systems
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
EP4342378A3 (en) 2016-12-27 2024-05-29 Dexcom, Inc. Systems and methods for patient monitoring using an hcp - specific device
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
WO2018136610A1 (en) 2017-01-19 2018-07-26 Dexcom, Inc. Flexible analyte sensors
CA3051914A1 (en) 2017-02-02 2018-08-09 Mcmaster University Bicarbonate as a potentiator for antimicrobial agents
WO2018148605A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
WO2018145219A1 (es) 2017-02-09 2018-08-16 Serani Mostazal Jorge Composición farmaceutica para la prevención y tratamiento de las adicciones a traves de un contracondicionamiento aversivo
US20170173262A1 (en) 2017-03-01 2017-06-22 François Paul VELTZ Medical systems, devices and methods
CN108619214A (zh) 2017-03-15 2018-10-09 王慎君 一种治疗肿瘤的药物
WO2018195455A1 (en) 2017-04-20 2018-10-25 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
BR112019022902A2 (pt) 2017-05-04 2020-05-19 Exciva GmbH composição, composição farmacêutica, uso da composição terapeuticamente eficaz, método e uso de uma composição terapeuticamente eficaz em um método de tratamento
US20210254056A1 (en) 2017-05-05 2021-08-19 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
EP3634422A4 (en) 2017-05-11 2021-05-26 Ramot at Tel-Aviv University Ltd. LEUKODYSTROPHY TREATMENT METHODS
US20180343812A1 (en) 2017-05-31 2018-12-06 Insectergy, Llc Cannabis farming systems and methods
US20190246591A1 (en) 2017-05-31 2019-08-15 Insectergy, Llc Insect and cannabis production systems and methods
US11938119B2 (en) 2017-05-31 2024-03-26 Insectergy, Llc Cannabis production systems and methods
EP3629899A4 (en) 2017-06-02 2021-04-21 Northwestern University THIN, SOFT, SKIN-MOUNTED MICROFLUIDIC NETWORKS FOR DETECTION AND ANALYSIS OF TARGET SUBSTANCES IN SWEAT
EP3928688B1 (en) 2017-06-23 2022-06-01 Dexcom, Inc. Transcutaneous analyte sensors, applicators therefor, and needle hub comprising anti-rotation feature
US11591277B2 (en) 2017-07-21 2023-02-28 The Florida State University Research Foundation, Inc. Photochemical separations and compositions
WO2019021158A1 (en) 2017-07-23 2019-01-31 Pluristem Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF ADDICTIONS
US20210315840A1 (en) 2017-09-25 2021-10-14 Small Pharma Ltd Solid oral dosage forms of ketamine derivatives
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
GB2588505B (en) 2017-10-09 2022-08-03 Compass Pathfinder Ltd Preparation of psilocybin
JP2021500948A (ja) 2017-10-19 2021-01-14 エレウシス ヘルス ソリューションズ ユーエス インコーポレイテッド サイケデリック薬剤療法の安全性を向上させる方法およびシステム
WO2019083939A1 (en) 2017-10-24 2019-05-02 Dexcom, Inc. PRECONNECTED ANALYTE SENSORS
GB201717629D0 (en) 2017-10-26 2017-12-13 Univ Oxford Innovation Ltd Treatment of unipolar depressive disorder
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
WO2019099745A1 (en) 2017-11-16 2019-05-23 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
AU2018381331A1 (en) 2017-12-04 2020-07-23 Victoria Cogger Compositions and methods for modulating liver endothelial cell fenestrations
FI128750B (en) 2017-12-21 2020-11-30 Helsingin Yliopisto Methods for determining the therapeutic effect of fast-acting antidepressants and related individual antidepressant therapy
WO2019161231A1 (en) 2018-02-16 2019-08-22 Botanical Process Solutions LLC Use of non-crystalline terpene alcohols for the inhibition of crystallization of cannabinoids
CA3093301A1 (en) 2018-03-08 2019-09-12 New Atlas Biotechnologies Llc Processes for the production of tryptamines
CN112533595A (zh) 2018-05-04 2021-03-19 感知神经科学公司 治疗物质滥用的方法
EP3807262A1 (en) 2018-06-12 2021-04-21 University of Washington Modified carbazoles as therapeutic agents
US20210267966A1 (en) 2018-06-21 2021-09-02 Robert Joseph Petcavich Method of Inducing Dendritic and Synaptic Genesis in Neurodegenerative Chronic Diseases
WO2020023084A1 (en) 2018-07-26 2020-01-30 Applied Biology, Inc. Taar receptor agonists for the treatment of alopecia
EP3829640A4 (en) 2018-08-01 2022-05-25 McMaster University METHOD OF INHIBITING MICROBIAL GROWTH
WO2020024071A1 (es) 2018-08-03 2020-02-06 Universidad Del Desarrollo Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción
WO2020041329A1 (en) 2018-08-20 2020-02-27 Yale University Combination therapy for treating or preventing depression or other mood diseases
US11337937B2 (en) 2018-08-27 2022-05-24 ReJoy TARR receptor agonists for sexual dysfunction
CN108929259A (zh) 2018-08-29 2018-12-04 四川青木制药有限公司 一种制备赛洛多辛中间体的方法
WO2020053196A1 (en) 2018-09-10 2020-03-19 Universität Basel Method for the biocatalytic alkylation of a substrate
EP3626772A1 (en) 2018-09-19 2020-03-25 Borealis AG Use of a melamine based compound and a hals compound as heat stabilizer in polymers
US11672861B2 (en) 2018-10-15 2023-06-13 The George Washington University Prussian blue nanoparticles functionalized with immune signals and applications thereof
US11045454B2 (en) 2018-12-06 2021-06-29 Palo Alto Investors LP Methods of treating food allergy conditions
CN113301888A (zh) 2019-01-18 2021-08-24 默克专利股份有限公司 制造固体施用形式的方法和固体施用形式
KR20210134313A (ko) 2019-01-30 2021-11-09 다이아몬드 테라퓨틱스 인크. 심리적, 인지적, 행동적 및/또는 기분 장애의 치료를 위한 5ht 수용체 아고니스트를 포함하는 조성물 및 방법
WO2020169850A1 (en) 2019-02-22 2020-08-27 Gh Research Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression
JP2022522659A (ja) 2019-02-22 2022-04-20 ジーエイチ リサーチ アイルランド リミテッド 精神障害の処置における使用のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン（５－ｍｅｏ－ｄｍｔ）を含む組成物
CN113784962A (zh) 2019-02-27 2021-12-10 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
EP3930708A4 (en) 2019-02-27 2023-02-15 The Regents Of The University Of California N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR THE TREATMENT OF BRAIN DISEASES
EP3934633A4 (en) 2019-03-07 2023-03-29 Arbormentis LLC COMPOSITIONS AND METHODS OF USE INCLUDING SUBSTANCES HAVING NEURAL PLASTICITY ACTIONS ADMINISTERED IN NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSES AND FORMULATIONS
WO2020185581A2 (en) 2019-03-08 2020-09-17 The Regents Of The University Of California Compositions and methods for modulating lipid and steroid metabolism
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11510596B2 (en) 2019-04-22 2022-11-29 Dexcom, Inc. Preconnected analyte sensors
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
BR112020025314A2 (pt) 2019-06-04 2021-03-09 Waveform Technologies, Inc. Processamento de sinal de sensor com calibração baseada em kalman
CA3088384C (en) 2020-06-17 2021-08-03 Psilo Scientific Ltd. Extraction of psychoactive compounds from psilocybin fungus
US20220249512A1 (en) 2019-06-27 2022-08-11 S.L.A. Pharmca AG Topical pharmaceutical compositions comprising diltiazem
AU2020308897A1 (en) 2019-06-27 2022-01-27 Holobiome, Inc. Therapeutic compositions and methods of using serotonin modulating microbiome-based interventions to treat serotonin-related diseases or disorders
DE102019117739A1 (de) 2019-07-01 2021-01-07 Felix Blei Arylalkyamin-, Pyrrol-, Indol- und Opiatderivatkonzentrationsbestimmungsverfahren sowie Testkit unter Verwendung dieses Verfahrens
WO2021003467A1 (en) 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
WO2021000054A1 (en) 2019-07-04 2021-01-07 Canopy Growth Corporation Cannabinoid derivatives
JP2022539400A (ja) 2019-07-04 2022-09-08 キャノピー グロウス コーポレイション カンナビノイド誘導体
EP3999490A4 (en) 2019-07-12 2023-03-08 Canopy Growth Corporation CANNABINOID DERIVATIVES
WO2021007661A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
EP3997095A4 (en) 2019-07-12 2022-12-28 Canopy Growth Corporation CANNABINOID DERIVATIVES
WO2021007662A1 (en) 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
US20220242856A1 (en) 2019-07-12 2022-08-04 Canopy Growth Corporation Cannabinoid derivatives
US20210015738A1 (en) 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
WO2021009374A1 (fr) 2019-07-17 2021-01-21 Universite De Reims Champagne Ardenne Composes de type liquide ionique, leurs procedes de preparation et leurs utilisations
US11766445B2 (en) 2019-07-18 2023-09-26 Concept Matrix Solutions Oral soft gel capsule containing psychedelic compound
WO2021016423A1 (en) 2019-07-23 2021-01-28 Caamtech Llc Compositions containing toad secretion compounds
WO2021016710A1 (en) 2019-07-30 2021-02-04 Tassili Life Sciences, Corp. Controlled release formulations of multiple active pharmaceutical agents, and psilocybe-derived agents in combination with cannabis-derived agents and methods for their use
US20210030787A1 (en) 2019-07-31 2021-02-04 Applied Biology, Inc. Methods for protecting hair follicles
CN112430187B (zh) 2019-08-07 2023-01-17 北京奇点势能科技有限公司 一种α,β-氘代胺类化合物、氘代药物及其制备方法
US20220273680A1 (en) 2019-08-13 2022-09-01 University Of Maryland, Baltimore Methods of Treating Psychological and Brain Disorders
EP4017859A4 (en) 2019-08-25 2023-08-23 Caamtech, LLC ALKYL QUATERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES
EP4049017A2 (en) 2019-08-30 2022-08-31 Tallinn University of Technology Apparatus and method for determination of banned substances
EP4031671A1 (en) 2019-09-16 2022-07-27 Danmarks Tekniske Universitet Yeast cells and methods for production of tryptophan derivatives
US11266314B2 (en) 2019-10-01 2022-03-08 Endra Life Sciences Inc. Method and system for determining a material type of an object of interest
EP4038192A4 (en) 2019-10-01 2023-11-01 Empyrean Neuroscience, Inc. GENETIC MANIPULATION OF MUSHROOMS TO MODULATE TRYPTAMINE EXPRESSION
US20220348586A1 (en) 2019-10-02 2022-11-03 Canopy Growth Corporation Cannabinoid derivatives
US20220340582A1 (en) 2019-10-02 2022-10-27 Canopy Growth Corporation Cannabinoid derivatives
US20230295106A1 (en) 2019-10-14 2023-09-21 The Regents Of The University Of California Ergoline-like compounds for promoting neural plasticity
WO2021072530A1 (en) 2019-10-15 2021-04-22 Tassili Life Sciences, Corp. Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder.
WO2021076849A1 (en) 2019-10-16 2021-04-22 Caamtech Llc New kratom compositions
US20210114973A1 (en) 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
MX2022004735A (es) 2019-10-21 2022-08-04 Esolate Ltd Composiciones que comprenden compuestos superfinos y su produccion.
MX2022004976A (es) 2019-10-28 2022-08-04 Univ Miami Métodos para la producción de psilocibina e intermediarios o subproductos.
HUE059403T2 (hu) 2019-11-07 2022-11-28 Small Pharma Ltd Vegyületek
US11246860B2 (en) 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression
CA3155976A1 (en) 2019-11-15 2021-05-20 Jacob Michael Vogan Biosynthetic production of psilocybin and related intermediates in recombinant organisms
US11660305B2 (en) 2019-11-19 2023-05-30 Turtle Bear Holdings, Llc Tryptamine compositions for enhancing neurite outgrowth
US20230150927A1 (en) 2019-11-26 2023-05-18 Canopy Growth Corporation Cannabigerol derivatives and use thereof as cannabinoid receptor modulators
JP2023503331A (ja) 2019-11-26 2023-01-27 キャノピー グロウス コーポレイション カンナビノイド誘導体
JP2023503330A (ja) 2019-11-26 2023-01-27 キャノピー グロウス コーポレイション カンナビノイド誘導体
US20230021957A1 (en) 2019-12-04 2023-01-26 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
EP4073033A4 (en) 2019-12-09 2024-01-24 Canopy Growth Corporation CANNABINOIDS DERIVATIVES
JP2023505517A (ja) 2019-12-09 2023-02-09 キャノピー グロウス コーポレイション カンナビノイド誘導体
AU2020399792A1 (en) 2019-12-13 2022-07-21 Folium Labs Inc. Complexes comprising a carbohydrate polymer and an active ingredient and processes for their preparation
WO2021138564A1 (en) 2019-12-31 2021-07-08 Cure Pharmaceutical Holding Corp. Oral dissolvable film and method of manufacturing and using the same
US20230102999A1 (en) 2020-01-10 2023-03-30 First Wave Bio, Inc. Deuterated niclosamide
BR112022015377A2 (pt) 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de psilocina como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
WO2021155467A1 (en) 2020-02-04 2021-08-12 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders
JP2023514559A (ja) 2020-02-05 2023-04-06 イエール ユニバーシティ 頭痛障害の幻覚剤処置
WO2021159213A1 (en) 2020-02-12 2021-08-19 Neonmind Biosciences Inc. Method for producing an extract of mushroom and mushroom extract made therefrom
CA3172046A1 (en) 2020-02-18 2021-08-26 Gilgamesh Pharmaceuticals, Inc. Specific tryptamines for use in the treatment of mood disorders
CA3169033A1 (en) 2020-02-27 2021-09-02 Andrew R. Chadeayne Crystalline bis-miprocin fumarate
US20210267985A1 (en) 2020-02-27 2021-09-02 Gerald Horn Compositions and methods for inducing enhanced brain function
US20220071946A1 (en) 2020-03-03 2022-03-10 Alte Verde Llc Cannabis Treatment of Insomnia, Pain, and Skin Conditions
US11801278B2 (en) 2020-03-05 2023-10-31 Cure Pharmaceutical, Inc. Method for obtaining an extract of a plant biomass
US20230162851A1 (en) 2020-03-09 2023-05-25 Eleusis Health Solutions Us, Inc. Methods and systems for enhancing clinical safety of psychoactive therapies
US20230140635A1 (en) 2020-03-12 2023-05-04 Bright Minds Biosciences Inc. 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators
WO2021188782A1 (en) 2020-03-19 2021-09-23 Caamtech, Inc. Crystalline psilacetin derivatives
EP4121045A4 (en) 2020-03-19 2024-04-10 Caamtech, Inc. CRYSTALLINE NORPSILOCIN COMPOUNDS
WO2021188870A1 (en) 2020-03-20 2021-09-23 Orthogonal Thinker, Inc. Psilocybin and psilocin containing compositions and methods of using and making the same
US11358934B2 (en) 2020-03-23 2022-06-14 Caamtech, Inc. Crystalline forms of psilacetin
US11332441B2 (en) 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
AU2021246519A1 (en) 2020-04-03 2022-11-17 Turtle Bear Holdings, Llc Compositions and methods for modulating inflammatory response
US11739060B2 (en) 2020-04-07 2023-08-29 Caamtech, Inc. Crystalline 5-methoxy-n,n-diallyltryptamine compounds
WO2021209815A1 (en) 2020-04-16 2021-10-21 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of psychedelics derivatives
CA3175679A1 (en) 2020-04-17 2021-10-21 Fabio Andrea CHIANELLI Use of psilocybin in the treatment of neurological brain injury and migraines
US20210322306A1 (en) 2020-04-21 2021-10-21 Cure Pharmaceutical Holding Corp. Oral dissolvable film with high load of polymeric binder
CA3177454A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2021234608A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
WO2021116503A2 (en) 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
CN116348448A (zh) 2020-07-24 2023-06-27 明德赛特制药公司 赛洛辛和赛洛西宾的可扩展合成路线
CA3186958A1 (en) 2020-07-29 2022-02-03 Judith BLUMSTOCK Extended release 5-ht receptor agonists for neurological conditions
WO2022038171A1 (en) 2020-08-18 2022-02-24 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
JP7422474B2 (ja) 2020-08-28 2024-01-26 サイビン ユーケー リミテッド 注射用製剤
US20220062237A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US20230355583A1 (en) 2020-10-02 2023-11-09 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
US11324762B2 (en) 2020-10-08 2022-05-10 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US20230405026A1 (en) 2020-11-06 2023-12-21 Mynd Life Sciences Inc. A Method of Treating Depression by Immune Modulation
JP2023551058A (ja) * 2020-12-01 2023-12-06 スモール ファーマ リミテッド 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
CA3210966A1 (en) 2021-02-10 2022-08-18 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
WO2022183288A1 (en) 2021-03-02 2022-09-09 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
US20220280482A1 (en) 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
US20220370413A1 (en) 2021-03-06 2022-11-24 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
WO2022195011A1 (en) * 2021-03-18 2022-09-22 Cybin Irl Limited Psilocybin analogs, salts, compositions, and methods of use
JP2024520017A (ja) 2021-05-26 2024-05-21 マインドセット ファーマ インコーポレイテッド 幻覚剤と脂肪酸との併用
WO2023036473A1 (en) 2021-09-08 2023-03-16 Cybin Irl Limited Combination drug therapies

Also Published As

Publication number Publication date
CA3177454A1 (en) 2021-11-25
US11834410B2 (en) 2023-12-05
MX2022014605A (es) 2022-12-16
US20230357147A1 (en) 2023-11-09
KR20230012501A (ko) 2023-01-26
US11242318B2 (en) 2022-02-08
US20230219889A1 (en) 2023-07-13
IL297492A (en) 2022-12-01
US11958807B2 (en) 2024-04-16
US20220119346A1 (en) 2022-04-21
US20240067605A1 (en) 2024-02-29
US20230202979A1 (en) 2023-06-29
US11746088B2 (en) 2023-09-05
AU2021276656A1 (en) 2022-11-24
CN115667217A (zh) 2023-01-31
US11724985B2 (en) 2023-08-15
US20230126298A1 (en) 2023-04-27
EP4153564A4 (en) 2024-06-19
EP4153564A1 (en) 2023-03-29
JP2023526856A (ja) 2023-06-23
US20230066286A1 (en) 2023-03-02
US20210363104A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
CO2022016662A2 (es) Derivados de triptamina deuterada y métodos de uso
CL2022003191A1 (es) Derivados de triptamina deuterada y métodos de uso
CL2020002055A1 (es) Macrociclos como moduladores del regulador de conductncia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos.
CL2020000367A1 (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
CL2023000416A1 (es) Compuestos de heteroarilo bicíclicos y usos de estos.
CO2019012473A2 (es) Antagonistas del receptor de hidrocarburos de arilo y usos de los mismos
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
CO2018001425A2 (es) Compuestos di-nucleótidos cíclicos como agonistas de sting
AR081859A1 (es) Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr
PE20190509A1 (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
PH12021550296A1 (en) Substituted indoles and methods of use thereof
CY1117427T1 (el) Παραγωγο πυραζολοκινολινης ως αναστολεις pde9
PE20151436A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
CL2023002731A1 (es) Análogos, sales, composiciones y métodos de uso de la psilocibina
PE20160201A1 (es) Bencil-1h-pirazol[3,4-b]piridinas y su uso
CO2022003457A2 (es) Triazolopirimidinas como inhibidores de a2a/a2b
CL2020003118A1 (es) Régimen de dosificación para el tratamiento de trastornos relacionados con pi3k.
CL2019002527A1 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer.
CO6541592A2 (es) Tiazoles biciclicos como moduladores alostericos de receptores de mglur5
PE20080941A1 (es) Compuestos triciclicos como agonistas del receptor de melatonina
MX2020004339A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
CO6650398A2 (es) Compuestos y composición farmacéutica para el tratamiento de los transtornos asociados a los receptores 5-ht1a y 5.ht2a
CO6251292A2 (es) Nuevos derivados 7-sustituidos de 3-carboxi-oxadiacino-quinolonas, su preparacion y su aplicacion como antibacterianos.
PE20130775A1 (es) Antagonistas no competitivos de receptores nicotinicos